Towards global consensus in the treatment of gastrointestinal stromal tumor

References

• Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu. Rev. Pathol.3, 557–586 (2008).
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), 64–67 (2009).
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. The NCCN Soft Tissue Sarcoma Clinical Practice Guidelines in Oncology (Version 1.2009I). National Comprehensive Cancer Network, PA, USA (2009).
   Google Scholar
• Blackstein ME, Blay JY, Corless C et al. Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Can. J. Gastroenterol.20(3), 157–163 (2006).
   PubMedGoogle Scholar
• Montemurro M, Dirnhofer S, Bornerc M et al. Diagnosis and treatment of GIST in Switzerland. Schweiz. Med. Forum8, 544–549 (2008).
   Google Scholar
• Nishida T, Hirota S, Yanagisawa A et al. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int. J. Clin. Oncol.13(5), 416–430 (2008).
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol.23(23), 5357–5364 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor ML, Metcalfe DD. KIT signal transduction. Hematol. Oncol. Clin. North Am.14(3), 517–535 (2000).
   PubMed Web of Science ®Google Scholar
• Bauer S, Hartmann JT, de Wit M et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int. J. Cancer117(2), 316–325 (2005).
   PubMed Web of Science ®Google Scholar
• Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol.24(15), 2325–2331 (2006).
   PubMed Web of Science ®Google Scholar
• Sym SJ, Ryu MH, Lee JL et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J. Surg. Oncol.98(1), 27–33 (2008).
   Google Scholar
• DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann. Surg.245(3), 347–352 (2007).
   PubMedGoogle Scholar
• Gronchi A, Fiore M, Miselli F et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic gist. Ann. Surg.245(3), 341–346 (2007).
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Nowecki Z, Nyckowski P et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J. Surg. Oncol.93(4), 304–311 (2006).
   PubMed Web of Science ®Google Scholar
• Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J. Surg. Oncol.99(1), 42–47 (2009).
   PubMedGoogle Scholar
• DeMatteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet373(9669), 1097–1104 (2009).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Owzar K, Antonescu CR et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the U.S. Intergroup Phase II trial ACOSOG Z9000. Program and Abstracts of the Gastrointestinal Cancers Symposium. Orlando, FL, USA, 25–27 January 2008 (Abstract 8).
   Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer42(8), 1093–1103 (2006).
   PubMed Web of Science ®Google Scholar
• Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol.25(9), 1107–1113 (2007).
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg.231(1), 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• Hassan I, You YN, Shyyan R et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann. Surg. Oncol.15(1), 52–59 (2008).
   PubMed Web of Science ®Google Scholar
• Langer C, Gunawan B, Schuler P, Huber W, Fuzesi L, Becker H. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br. J. Surg.90(3), 332–339 (2003).
   PubMed Web of Science ®Google Scholar
• Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol.20(18), 3898–3905 (2002).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol.26(4), 620–625 (2008).
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347(7), 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the KIT receptor tyrosine kinase: S0033. J. Clin. Oncol.26(4), 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet364(9440), 1127–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Chen H, Pruitt A, Nicol TL, Gorgulu S, Choti MA. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J. Gastrointest. Surg.2(2), 151–155 (1998).
   PubMedGoogle Scholar
• Bonvalot S, Eldweny H, Pechoux CL et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann. Surg. Oncol.13(12), 1596–1603 (2006).
   PubMed Web of Science ®Google Scholar
• Hasegawa J, Kanda T, Hirota S et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int. J. Clin. Oncol.12(3), 212–217 (2007).
   Google Scholar
• Hohenberger P, Wardelmann E. [Surgical considerations for gastrointestinal stroma tumor]. Chirurg77(1), 33–40 (2006).
   Google Scholar
• Adenis A, Cassier P, Bui BN et al. Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial? J. Clin. Oncol.26(Suppl.), (2008) (Abstract 10522).
   Google Scholar
• Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann. Surg. Oncol.11(5), 465–475 (2004).
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet358(9291), 1421–1423 (2001).
   PubMed Web of Science ®Google Scholar
• Technische Universität München. Csti571-bde43. Open-label trial of neoadjuvant imatinib mesylate (Glivec) in patients with locally advanced malignant gastrointestinal stromal tumors (GIST) expressing c-KIT or platelet-derived growth factor receptor-α. (NCT identifier: NCT00112632) (2009).
   Google Scholar
• Radiation Therapy Oncology Group, National Cancer Institute (NCI), American College of Radiology Imaging Network, Eastern Cooperative Oncology Group. RTOG S-0132. A Phase II trial of neoadjuvant/adjuvant STI-571 (Gleevec NSC #716051) for primary and recurrent operable malignant GIST expressing the KIT receptor tyrosine kinase (CD117). (NCT identifier: NCT00028002) (2009).
   Google Scholar
• DeMatteo RP, Gold JS, Saran L et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer112(3), 608–615 (2008).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol.23(2), 70–83 (2006).
   PubMed Web of Science ®Google Scholar
• DeMatteo R, Owzar K, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Program and Abstract of the American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 1–5 June 2007 (Abstract 10079).
   Google Scholar
• Shen L, Li J, Li J, Gong J, Wu A. Adjuvant post-surgery therapy with imatinib in intermediate or high-risk gastrointestinal stromal tumour (GIST) patients: interim analysis from a single centre comparison study. Ann. Oncol.19(Suppl. 8), Viii 267. (2008) (Abstract 870pd).
   Google Scholar
• Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol.33, 459–465 (2002).
   PubMed Web of Science ®Google Scholar
• Kang Y, Kang BW, Ryu M et al. A Phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors with c-KIT exon 11 mutation. Presented at: Gastrointestinal Cancers Symposium: Science and Multidisciplinary Management of GI Malignancies. San Francisco, CA, USA, 15–17 January 2009 (Abstract 95).
   Google Scholar
• European Organization for Research and Treatment of Cancer, Italian Sarcoma Group, Federation Nationale des Centres de Lutte Contre le Cancer, Sarcomas GEdIe. EORTC 62024. Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant imatinib mesylate (Glivec) versus no further therapy after complete surgery. (NCT identifier: NCT00103168) (2009).
   Google Scholar
• Scandinavian Sarcoma Group. SSGXVIII/AIO. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST with a high risk of recurrence. (NCT identifier: NCT00116935) (2009).
   Google Scholar
• Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol.25(13), 1760–1764 (2007).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, van Glabbekke M, Verweij J et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? J. Clin. Oncol.24(18s), (2006) (Abstract 9510).
   Google Scholar
• Choi H, Charnsangavej C, Faria SC et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol.25(13), 1753–1759 (2007).
   PubMed Web of Science ®Google Scholar